If awarded, you will:
- Co-develop and validate the solution within the GHU Paris, GCSMS 91 or FOCH Hospital and GIP RESAH.
- Receive funding up to 60.000€ [40.000€ for Challenges 1 to 4 and 60.000€ for Challenge 5, completed with a maximum funding...
Adrenomed AG, the vascular integrity company, today announced that the Phase II clinical trial design of AdrenOSS-II was published by the peer-reviewed open access journal BMJ Open. The currently ongoing Phase II trial is conducted to assess the...More
Since the beginning of February this year, Christine Goffinet has been the BIH Professor of Virology at the Berlin Institute of Health (BIH) and the Institute of Virology at Charité – Universitätsmedizin Berlin. She is conducting research into the...More
Das von Horizon 2020 geförderte Projekt STARS "Empowering Patients by Professional Stress Avoidance and Recovery Services" wird die Ausschreibung am 1. Februar 2019 veröffentlichen. Die Frist für die Einreichung von Vorschlägen endet am 30. April...More
Several research groups at Berlin Institute of Health (BIH) are working on digitally combating cancer. The main goal is to combine and jointly evaluate existing information. With 500,000 new cancer cases every year in Germany alone, it is worthwhile...More
Researchers from Charité – Universitätsmedizin Berlin have discovered a protective mechanism which is used by the body to protect intestinal stem cells from turning cancerous. The body’s innate immune system was found to play a pivotal role in this...More
Call ID: H2020-JTI-IMI2-2019-17-two-stage
Action Type: RIA – Research and Innovation ActionsMore
Be aware and apply!More
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and ProBioGen, a premier German service and technology provider, today announced a multi-year research...More